The KOSDAQ listed Genome & Company has acquired a manufacturing facility in the US to enter the microbiome contract development and manufacturing organization (CDMO) business. Through the acquire, the company aims to rise to a leader in both R&D and production in the microbiome market, a field with high growth potential.

On the 8th, Genome & Company announced that it had acquired 966,502 shares of List Labs in the US in cash. This is equivalent to 27.17% of the company’s net worth. To internalize the production of microbiome treatment and diversify the company’s business, Genome & Company acquired 60% of List Lab’s shares and became the major shareholder of List Labs

Genome & Company